Capvizr
THE DEAL, AT A GLANCE

Draig Therapeutics

From the announcement
01
MoleculesDrug research
Medicine development
What it doesDraig Therapeutics is developing transformative, best-in-class neuropsychiatric therapies to restore the brain to a healthier state, enabling patients to live their best…From the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗
02Who is involvedBacked by your use of their servicesFrom the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗
03What happenedDraig Therapeutics raised $65M Series B, announced 2026-07-14From the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗
04Why it mattersDraig Therapeutics' $65M Series B is a mid-pack Healthcare & Life Sciences capital-flow signal, ranking at the 55th percentile by size while aligning with recent $65M to…From the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗
Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗

Draig Therapeutics · Financing Record

Explore source-linked visual explanations for Draig Therapeutics. Unsupported claims are withheld while source review continues.

Record 8114 · Recorded date: 2026-07-14

Explore company records →
Free weekday briefing

Know which funding rounds matter before the first call.

Source-linked rounds, lead investors, and the signal behind the capital. One five-minute read.

Free · Unsubscribe anytime